SUPPLIVEN

This brand name is authorized in France.

Active ingredients

The drug SUPPLIVEN contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII 8F2SXI1704 - SODIUM MOLYBDATE DIHYDRATE
 
Read more about Sodium molybdate
2
UNII HIW548RQ3W - SODIUM SELENITE
 

Selenium is an essential trace element. In human, selenium compounds are glutathione peroxidase and a selenium protein P found in the plasma. Deficiency of selenium has been associated with an endemic form of cardiomyopathy, Keshan disease and with Kaschin-Beck disease, an endemic osteoarthropathy which causes a severe deformity of the joints.

 
Read more about Sodium selenite
3
UNII 0I2XIN602U - FERRIC CHLORIDE HEXAHYDRATE
 
Read more about Ferrous chloride
4
UNII 86Q357L16B - ZINC CHLORIDE
 
Read more about Zinc chloride
5
UNII QQE170PANO - MANGANESE CHLORIDE
 

Manganese is required for the synthesis of the mucopolysaccharides of cartilage, glucose utilisation, steroid biosynthesis and for the activity of pyruvate carboxylase. It is bound to arginase of the liver and activates many enzymes.

 
Read more about Manganese
6
UNII S2QG84156O - CUPRIC CHLORIDE
 
Read more about Copper chloride
7
UNII KB1PCR9DMW - CHROMIC CHLORIDE
 
Read more about Chromic chloride
8
UNII 8ZYQ1474W7 - SODIUM FLUORIDE
 

Sodium fluoride is indicated for the prevention of dental caries in adolescents and adults, particularly amongst patients at risk from multiple caries (coronal and/or root caries). The primary mode of the caries preventative action of fluoride is post-eruptive, i.e topical action. Systemic fluoride supplements are believed also to act mainly topically (i.e during ingestion, via saliva).

 
Read more about Sodium fluoride
9
UNII 1C4QK22F9J - POTASSIUM IODIDE
 

Potassium iodide is indicated as a thyroid-blocking agent to prevent the uptake of radioactive iodine, for example after a nuclear accident or during a nuclear medicine investigation before administering a radioiodinated compound, which is metabolised to iodide or which contains radioiodine impurities.

 
Read more about Potassium iodide

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
B05XA31 Electrolytes in combination with other drugs B Blood and blood forming organs → B05 Blood substitutes and perfusion solutions → B05X I.V. solution additives → B05XA Electrolyte solutions
Discover more medicines within B05XA31

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
FR Base de données publique des médicaments 60307630

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.